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This paper considers the problem in aggregate data meta-analysis of studies
reporting multiple competing binary outcomes and of studies using different sum-
mary formats for those outcomes. For example, some may report numbers of
patients with at least one of each outcome while others may report the total number
of such outcomes. We develop a shared parameter model on hazard ratio scale
accounting for different data summaries and competing risks. We adapt theoretical
arguments from the literature to demonstrate that the models are equivalent if
events are rare. We use constructed data examples and a simulation study to find an
event rate threshold of approximately 0.2 above which competing risks and differ-
ent data summaries may bias results if no adjustments are made. Below this thresh-
old, simpler models may be sufficient. We recommend analysts to consider the
absolute event rates and only use a simple model ignoring data types and compet-
ing risks if all of underlying events are rare (below our threshold of approximately
0.2). If one or more of the absolute event rates approaches or exceeds our informal
threshold, it may be necessary to account for data types and competing risks
through a shared parameter model in order to avoid biased estimates.
KEYWORD S
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1 | INTRODUCTION
Aggregate data meta-analysis synthesizes the results on out-
comes that have been reported by studies such as random-
ized controlled trials (RCTs). In meta-analysis of binary
outcomes, a common complication is that RCTs report more
than one outcome and that these outcomes are correlated or
indeed competing; for instance, an RCT may censor patients
who experience a stroke, and thus, a later myocardial infarc-
tion will not be reported.1,2 A further complication is that
some studies may report different aggregate summary format
of the outcomes of interest; for example, some may report
numbers of patients with at least one of each outcome, while
others report the total number of each outcome, counting
patients more than once. These issues of competing risks
and differently reported data are also present in network
meta-analysis (NMA) that aims to compare multiple inter-
ventions via connected networks of evidence.3
It is known from the statistical literature that competing
risks have limited impact if events are rare, and scenarios
have been identified where it is not necessary to account for
competing risks in meta-analysis.4,5 However, if events are
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not rare, then not accounting for these complications can
affect treatment comparisons.6 Differences in conclusions of
meta-analyses and NMA are important as they are the rec-
ommended approach for treatment effect estimation and
indirect comparison by health care authorities (eg, National
Institute of Healthcare and Decision Making in the United
Kingdom) and international medical decision-making socie-
ties (eg, International Society for Pharmacoeconomics and
Outcomes Research and Society for Medical Decision
Making).7,8 Despite the importance, meta-analysis and
NMA on outcomes that are not rare commonly use simple
analyses that may be biased. Examples can be found in
depression,9,10 relapsing remitting multiple sclerosis,11 and
5-year survival and mortality rates in a range of cancers.12
Furthermore, health economic decision models may require
treatment effects on multiple outcomes, requiring that the
interdependence be explicitly modelled.13 The bias in results
from ignoring outcome interdependence can be magnified if
used in such decision models.14
Several approaches have been proposed to account for
competing risks in meta-analysis and NMA, including
modelling functional relationships between outcomes,1 lin-
ear regression of outcomes of interest on surrogate
outcomes,15,16 and normal approximations.17 If individual
patient data are available from the RCTs, within-study corre-
lation between outcomes in a meta-analysis can be explicitly
modelled,18 but it is rare for such individual patient data to
be available for all RCTs. Meta-analysis of the cumulative
incidence function, the expected proportion of cause-specific
events over time, has also been considered.19
There has been less work developing methods to combine
differently summarized data in (network) meta-analysis with
event outcomes. Models with different treatment effects for
each data summary but related by a common random effect
have been proposed.20 Due to its greater flexibility and
explicit modelling of underlying relationships, we adopt the
approach of shared parameter models.3,21,22 These have been
used to combine binomial data with estimated log odds
ratios or mean survival.23 Illustrating their flexibility, shared
parameter models have also been used to combine continu-
ous, categorical, and binary data.24
In this paper, we develop a novel shared parameter com-
peting risk model to simultaneously account for all these
complications in a NMA. This extends earlier work on com-
peting risks and modelling of functions of shared parame-
ters.1,25 Our work is motivated by a NMA comparing
anticoagulants for the prevention of stroke in atrial fibrilla-
tion. We investigate theoretical reasons why the adjustments
are not necessary when events are rare and use constructed
data to identify scenarios where results can be substantially
biased if an unadjusted model is used. We also present
results from a simple simulation study exploring the
conditions under which adjusted and unadjusted analyses
can give biased results.
2 | MOTIVATING EXAMPLE:
DIRECTLY ACTING ORAL
ANTICOAGULANTS FOR STROKE
PREVENTION IN ATRIAL
FIBRILLATION
The objective of our case study was to compare first-line
treatments for the prevention of stroke, myocardial infarction
(MI), bleed, and death in atrial fibrillation. Our case study is
based on a systematic literature review and Bayesian NMA
comparing treatments for the prevention of stroke in atrial
fibrillation (AF), which has been described previously in the
literature.26,27 AF is the most common cardiac arrhythmia
and substantially increases the risk of thromboembolic stroke
due to blood pooling in the left atrium and systemic emboli-
zation to the brain.28 Treatments for prevention of stroke in
AF include the anticoagulant warfarin as well as the more
recently developed directly acting (or nonvitamin K antago-
nist) oral anticoagulants (DOACs).29,30 However, all antico-
agulants carry the risk of internal bleeding.31 Our NMA
compared warfarin (international normalized ratio (INR) tar-
get range 2-3) with the DOACs apixaban (twice daily 5 mg),
dabigatran (twice daily 150 mg), edoxaban (once daily 60
mg), and rivaroxaban (once daily 20 mg).
The four outcomes of interest were ischaemic stroke, MI,
clinically relevant bleeding, and death. The systematic litera-
ture review identified 20 RCTs comparing DOACs to warfa-
rin and reporting on these outcomes.26,27 However, an
additional thirteen outcomes were reported by these studies:
bleeding (distinct from clinically relevant bleeding), minor
bleeding, fatal bleeding, transient ischaemic attack (TIA),
fatal stroke, composite clinically relevant bleeding (again
distinct from clinically relevant bleeding), hospital admis-
sion, death (cardiovascular specific), arterial event, pulmo-
nary embolism, extracranial minor bleeding, systemic
embolism (SE), and intracranial bleeding (ICH) (to which
we added haemorrhagic stroke, under clinical advice).
A further complication was that the data from the RCTs
were summarized in three different formats, which are
described in Table 1. Data format 1 summarizes only the first
event for each individual, after which they were assumed
censored; this data format involves competing risks as
patients reporting one outcome are censored and cannot
report further outcomes. Data format 2 summarizes only the
total number of individuals experiencing at least one of each
outcome. In this second form of summary, each individual
may count towards more than one outcome, but only once
for each outcome. Data format 3 gives the total number of
events of each outcome across all patients. Data formats 2
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and 3 do not involve competing risks. Five studies reported
data format 1, 13 reported format 2, and two reported format
3. Although our interest is only on the four key outcomes of
ischaemic stroke, MI, clinically relevant bleeding, and death,
as these are competing risks, the additional 13 outcomes
must also be modelled. Further details on the data are
included in the Supporting Information.
3 | METHODS
We first denote the number of studies in our analysis Ns and
number of arms Ki in trial i = 1,…,Ns. Let r
jð Þ
ikm be the num-
ber of events in study i, arm k = 1,…,Ki (with data format
j = 1,2,3), and outcome m (m = 1,…,M). In our application,
the final event M represents mortality. The treatment tik and
number randomized nik are independent of outcome m. The
total patient years at risk or exposure time, which is also the
same for every outcome, is denoted Eik, while mean patient
follow-up time is Tik = Eiknik . Not every study necessarily
reports each outcome.
3.1 | Simple odds ratio model: separate NMA
models for each outcome, ignoring data type
The simplest approach is to model each outcome separately
(ignoring the competing risk nature of the outcomes), to treat
all the studies as estimating the same probability of outcome
(regardless of data format), and to ignore the follow-up time
or exposure. In this case, a binomial likelihood is given inde-
pendently for each outcome, with the number randomized,
nik, as the denominator.
The likelihood for each outcome m reported in arm k of
study i is
r jð ÞikmeBin pikm,nikð Þ, for each data format type j=1,2,3:
This is the number of events r jð Þikm of outcome m which
occurred in the nik patients in arm k of trial i. We then use a
fixed-effect NMA model assuming consistency of effects on
the log odds scale, so that the relative treatment effects are
log odds ratios3
logit pikmð Þ= μim + dtikm−dti1m
where the baseline log odds μim of outcome m are treated as
nuisance parameters and vague priors are placed on them
μimeN 0,0:0001ð Þ
and vague priors are also placed on the log odds ratios
dtm for all outcomes m and treatments t
dtmeN 0,0:0001ð Þ for t 6¼ 1
d1m =0
Vague priors may introduce numerical issues with con-
vergence; if this occurs, less diffuse priors can be explored.
Preliminary investigations found that a fixed rather than
random treatment effect model was adequate for the AF
application. The key implicit assumption of this model for
our purposes is that rikm is the number of patients who have
at least one event of outcome m and that patients who have
multiple such events are only counted once. The interpreta-
tion of dtm is therefore of a log odds ratio of the event regard-
less of whether it is the first or a subsequent event. We now
describe alternative models that do not make this
assumption.
3.2 | Shared parameter model on hazard
ratios accounting for competing risks and
different data summaries
The first modification is to put the model on the log hazard
ratio rather than log odds ratio scale, in order to estimate a
single model incorporating all the different data types. In our
shared parameter models, λikm is the hazard of outcome m in
arm k of study i. Although the interpretation of the number
TABLE 1 Different data formats and models included in the network meta-analysis
Data Format
Index in Model Data Format
Competing
risksRisks?
Number of
studiesStudies
Likelihood and Link Function in
Shared Parameter Model
j = 1 Reports only first event for each
patient, after which they are
censored
Yes 5 Poisson for total number of events,
multinomial for each outcome with
log link
j = 2 Total number with at least one of each
outcome
No 13 Binomial likelihood with
complementary log log link. Poisson
with log for death
j = 3 Total number of events across patients No 2 Poisson for total number of events
with log link
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of events r jð Þikm is different for each of the data type j, the inter-
pretation of the λikm is always the same. The NMA model is
put on the log hazard scale
log λikmð Þ=ωim + htikm−hti1m ð1Þ
where the baseline log hazards ωim are treated as nui-
sance parameters and priors are placed on them
ωimeN 0,0:5ð Þ
with the precision 0.5 corresponding to a standard devia-
tion of approximately 1.41. The log hazard ratios, htm, for
treatment t relative to treatment 1 for outcome m are given
the same priors
htmeN 0,0:5ð Þ for t 6¼ 1
h1m =0
More vague priors did not converge with our atrial fibril-
lation example but are explored in simulation below. We rec-
ommend exploring more diffuse priors in other applications
of the model.
A different likelihood and link function is used for each
of the three data formats j, but all contribute evidence to the
λikm and thus to the treatment effects htm.
3.2.1 | Studies reporting number of patients
whose first event is of a given type: data type
j = 1
In studies of this type, only the first event is recorded for
each individual, and they are assumed censored from the
time at which that first event occurs. The outcomes are there-
fore competing risks and must be modelled jointly. This type
of data are labelled j = 1, and the r 1ð Þikm are the number of indi-
viduals with first event of type m. We label Rik =
PM
m=1
r 1ð Þikm
the total number of patients having an event of any type in
arm k of study i. Recalling that Eik is the observed person
years at risk, our model for this data uses a Poisson and mul-
tinomial likelihood
RikePoisson EikXM
m=1
λikm
 !
r 1ð Þik1,r
1ð Þ
ik2,…,r
1ð Þ
ikM
 eMultinomial λik1PM
m= 1λikm
,…, λikMPM
m=1λikm
 !
;Rik
 !
The hazards λikm are then modelled on the log scale via
Equation (1).
3.2.2 | Studies reporting number of patients
experiencing at least one event for each type:
data type j = 2
In this type of study, each patient may count towards more
than one event type, but only once for each event type. There
are therefore no competing risks to consider. This data are
labelled j = 2, and r 2ð Þikm are here the number of patients with
at least one event of type m. As mortality can only occur
once, the number of mortalities r 2ð ÞikM must be modelled differ-
ently to other events. Assuming an average follow-up time
Tik for each patient, the likelihood for nonmortality events is
r 2ð Þikmebinomial pikm,nikð Þ
This is the same as in the simple model, but pikm is now
the probability that an individual has one or more events of
type i over the mean follow-up Tik. The appropriate link
function is therefore the complementary log-log
cloglog pikmð Þ= log Tikð Þ+ log λikmð Þ
The likelihood for the number of mortalities is
r 2ð ÞikMePoisson EikλikMð Þ
The hazards λikm are again linked to the log hazard ratios
via Equation (1).
3.2.3 | Studies reporting the total number of
events of each type: data type j = 3
In this final type of study, data are labelled j = 3, and r 3ð Þikm
are the total number of events of type m, including repeat
events with patients, for given person years at risk Eik. The
likelihood is simply
r 3ð ÞikmePoisson Eikλikmð Þ
with λikm modelled by Equation (1). This completes our
specification of a shared parameter model accounting for the
three types of study data and for competing risks when they
are present.
3.3 | Equivalence of simple and shared
parameter models if events are rare:
asymptotic arguments
We have so far developed two models. Section 3.1 developed
a simple odds ratio model that assumes all outcomes are
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independent and models the three data summary types in the
same way. Section 3.2 developed a shared parameter hazard
ratio model that uses different models for the three data types
j = 1,2,3. In the present section, we give theoretical demon-
strations that if events are rare, the models for these three
data summaries are equivalent. As odds and hazard ratio
models are equivalent if events are rare, the hazard ratio
model for studies reporting number of patients with at least
one of each event type described in Section 3.2.2 (data type
j = 2) is equivalent to the simple odds ratio model of Section
3.1.32 The demonstrations below therefore establish that the
simple and shared parameter models give equivalent results
if events are rare. Note that the equivalence of competing
and noncompeting risk NMA is further established in the
Supporting Information, but our argument below does not
rely on this result.
3.3.1 | Equivalence of models for types 1 and
3 under rare events
Recall that data of type 1 were number of patients whose
first event was of a given type. Total number of events
Rik =
PM
m=1
r 1ð Þikm was modelled using a Poisson distribution
with parameter Eik
PM
i=1
λikk while the number of first events of
each type r 1ð Þik1,r
1ð Þ
ik2,…,r
1ð Þ
ikM
 
followed a multinomial distri-
bution. Dropping the indices for arm k and study i the likeli-
hood is proportional to
L1 r
1ð Þ
1 ,…, r
1ð Þ
M
 
/
YM
m=1
λmP
λl
 r 1ð Þm
ERe−E
P
λl
Noting R=
PM
m=1
r 1ð Þm gives
L1 r
1ð Þ
1 ,…, r
1ð Þ
M
 
/
YM
m=1
λr
1ð Þ
m
m
  1P
λl
 R
ERe−E
P
λl
Data of type 3 are the total number of each event, so the
likelihood is a product of M Poisson distributions with
parameters Eλm. Removing constants, this becomes
L3 r
3ð Þ
1 ,…, r
3ð Þ
M
 
/
YM
m=1
λr
1ð Þ
m
m
 
e−E
P
λl
L1 and L3 are always different by a, parameter dependent
and therefore nonconstant, factor of 1P
λl
 R
, but this will
be minimized when R (the total number of events) is small,
which is when events are rare.
3.3.2 | Equivalence of models for types 2 and
3 under rare events
In this case, we only need to consider nonmortality events as
the numbers of mortalities for type 2 and 3 data are both
modelled as Poisson likelihoods with parameter EikλikM. As
events are assumed independent under both models, we con-
sider only one event m. Recall the type 2 likelihood
r 2ð Þikmebinomial pikm,nikð Þ
cloglog pikmð Þ= log Tikð Þ+ log λikmð Þ ð2Þ
Following the law of rare events,33 this binomial distribu-
tion can be approximated by a Poisson if nik is large and pikm
is small (ie, rare events)
r 2ð ÞikmePoisson pikmnikð Þ ð3Þ
Noting the relation between mean follow-up and expo-
sure time Tik = Eiknik , Equation (2) gives a further expression
for the event probability
pikm = 1−e
λikmEik=nik
If the rate λikm is low, the exponential can be approxi-
mated using lim
x!0
ex =1−x, and substituting for pikm in the
Poisson likelihood of Equation (3) gives
r 2ð ÞikmePoisson Eikλikmð Þ
This is exactly the likelihood for data of type 3.
This completes our demonstration that the models for the
three data types are equivalent and therefore that the shared
parameter hazard ratio model is equivalent to the simple
odds ratio model, if events are rare.
3.4 | The impact on results if events are more
common: constructed data
We explored the conditions under which the simple and
shared parameter models will give different results. This was
done by constructing AF datasets with increased rates of
events. We increased the number of events of each outcome,
while keeping the number of patients constant, in each RCT
by factors of 1 (base case), 2, 5, 10, and 20. We capped the
number of events of each type at the number of patients.
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These five constructed datasets were then analyzed using
both the simple odds ratio model and the shared parameter
hazard ratio model.
3.5 | Simulation study
As the AF example was a single replicate, we conducted a
simulation study to compare the NMA results of the simple
odds ratio and shared parameter models on a variety of simu-
lated sets of trial results. Best practice guidelines for simula-
tion studies were followed.34 We simulated datasets from the
parametric shared parameter model to (1) explore the perfor-
mance of estimating a shared parameter model and (2) iden-
tify conditions where the simple odds ratio approach
performed adequately.
All our scenarios assume that there are three treatments
being studied on two outcomes over 10 RCTs. We do not
specify if outcomes 1 or 2 are positive (eg, recovery) or neg-
ative (eg, stroke), but for simplicity, we specify neither are
death to avoid issues of censoring. Simulated studies were
all two-arm RCTs with 100 patients on each arm and a
follow-up of 1 year. Simulated results of the RCTs were
modelled to be in one of the three formats of the AF exam-
ple. Full details of the data formats and included treatments
are in Table 2. Treatment 1 was modelled as the reference
treatment. Log hazard ratios of treatment 2 relative to treat-
ment 1 were −0.25 and 0.25 on outcomes 1 and 2, respec-
tively (in Equation (1), these are denoted h2m for m = 1,2).
Log hazard ratios of treatment 3 relative to treatment 1 were
0.25 and −0.25 on outcomes 1 and 2, respectively (h3m for
m = 1,2). The log hazards on treatment 1 in each trial (den-
oted ωim for i = 1,…,10) were set such that the average event
rate for each outcome (λikm for trial i, treatment k = 1,2,3,
outcome m) was 0.05, 0.1, 0.2, 0.3, and 0.4. This set of five
event rates for each outcome gives 25 scenarios in total.
Numbers of events of each outcome on each arm were simu-
lated randomly, and the results fed into the simple odds ratio
and shared parameter models.
The targets of estimation by the models were the hkm for
treatments k = 2 and k = 3 on both outcomes, and the perfor-
mance of each model was assessed over estimates h^km lð Þ on
each simulation l = 1,…,nsim. We prespecified that the bias
( 1nsim
P2
k=1
Pnsim
l=1h^km lð Þ−hkm) and coverage (probability that
h^
low
km lð Þ ≤ hkm ≤ h^
high
km lð Þ for all l and k) would be the performance
measures. Number of simulations nsim was calculated to be
2500 so that the mean squared error of the coverage was less
than 0.01 and for bias was 0.02.34
To explore the impact of priors in the shared parameter
model when events are rare, we repeated the simulation
study for event rates 0.05 and 0.1, and again with nsim = 2500,
but using baseline log hazard prior for outcome m of study i
ωimeN 0,0:05ð Þ
and log hazard ratio prior, for treatment t relative to treat-
ment 1
htm~N(0,0.05) for t 6¼ 1
These correspond to standard deviations of approxi-
mately 4.47. More vague priors were not found to reliably
converge for the simulation study data.
3.6 | Model implementation
The NMA models presented were implemented in
OpenBUGS version 3.2.3 rev 1012.35 We used two chains
with 60 000 iterations for burn-in and 30 000 iterations for
posterior sampling in the AF base case and constructed data
examples. The simulation study, due to greater computa-
tional resources required, used two chains but with 30 000
iterations for burn-in and 10 000 iterations for sampling.
Convergence was assessed using Brooks-Gelman-Rubin
(GBR) statistics and visual inspection of the history plots.36
Data were cleaned and saved in the appropriate BUGS for-
mat in the R programming language version 3.1.2.37 The
inflation of event rates, summarizing of results, and genera-
tion of figures necessary for the constructed data examples
were conducted in R, as was the simulation study. Code for
the novel shared parameter model is presented in the
Supporting Information while code for simulation study is
available on request.
TABLE 2 Studies included in simulation study
Study
Data
Format
Number of
Patients on
Treatment
1
Number of
Patients on
Treatment
2
Number of
Patients on
Treatment
3
1 1 100 100 0
2 1 100 0 100
3 1 100 100 0
4 1 0 100 100
5 2 100 100 0
6 2 100 0 100
7 2 100 0 100
8 3 0 100 100
9 3 100 0 100
10 3 100 100 0
Notes. All are two-arm RCTs with follow-up of 1 year.
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4 | RESULTS
4.1 | Comparison of model results
The results of the two models are presented in Table 3. The
“simple OR” results correspond to the simple model on odds
ratios while the “shared parameter HR” results correspond to
the hazard ratios estimated by the shared parameter model.
These odds and hazard ratios are relative to the reference of
warfarin (INR 2-3). Odds ratios or hazard ratios greater than
1 suggest worse outcomes (eg, higher odds or hazard of
stroke) on the DOAC compared with warfarin. If the 95%
credible intervals include 1, they suggests that we cannot
rule out no difference in treatment effect. Comparing across
DOACs, higher odds or hazard ratios again indicate worse
outcomes while overlapping 95% credible intervals suggest
uncertainty about which performs better. Comparison of
treatments has been described and interpreted in detail in an
earlier publication.26 Broadly, apixaban performs well (lower
odds and hazards) across all outcomes of stroke, MI, death,
and bleed. Dabigatran has the lowest odds and hazards on
stroke but elevated danger of MI and bleed. All DOACs have
lower odds/hazards of death and perform similarly to each
other.
The methodologically interesting finding is that the
results of the simple and shared parameter models are very
similar. The point estimates and the limits of the 95% credi-
ble intervals are either very similar or identical. The greatest
divergence between the models is in MI for dabigatran, per-
haps because this is the least rare event, but even in this case,
the difference in results is small.
4.2 | Results of constructed data examples
Mean and 95% credible intervals for the odds and hazard
ratios estimated by the two models under the increased event
rate scenarios are summarized for apixaban and dabigatran
in Tables 4 and 5, respectively. Results for rivaroxaban and
edoxaban are presented in the Supporting Information.
Under the base case, the event rates are sufficiently low that
the two models agree in their point and uncertainty esti-
mates. However, as the rates are gradually increased, the
point estimates and credible intervals become more different.
This divergence in results is illustrated in Figures 1 and 2. It
appears that as the event rate exceeds 0.2, the credible inter-
vals no longer overlap and conclusions change substantially.
4.3 | Simulation study results
The bias results on outcomes 1 and 2 are presented in
Tables 6 and 7, respectively, while coverage results on out-
comes 1 and 2 are presented in Tables 8 and 9, respectively. T
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In general, the shared parameter model has higher bias and
lower coverage on each outcome than the simple odds ratio
model when events are rare, but this reverses as event rates
of the outcome being studied increase. Limited data and
influence of the prior distributions are a likely explanation
for the superior performance of the simple model when
events are rare. The approximate crossover point on both
bias and coverage appears to be between 0.1 and 0.3.
Increasing the rate of outcome 2 has less impact on the bias
and coverage of outcome 1 (eg, rate of outcome 2 in the bias
for outcome 1 presented in Table 6) than increasing the rate
of outcome 1 itself, and vice versa. However, this impact of
increasing the rate of the other outcome increases with the
rate of the outcome being studied. Spot checks on BGR sta-
tistics and history plots for runs of the simulation suggested
good convergence of both models for all event rates.
Our simulation results comparing the simple and shared
parameter models, when vaguer priors are used in the latter,
are presented in Table 10. These were explored for only the
cases where data are weakest, namely, the cases where event
rates were the rare 0.05 and 0.1. We see that this does not
improve either the bias or coverage of the shared parameter
models for rare events.
5 | DISCUSSION
In this paper, we have considered the common situation
where studies report multiple, potentially competing out-
comes and where studies summarize outcomes in different
ways. We developed a novel shared parameter model for
NMA that accounts for the competing risks and different
summaries. We found that this complex model gave almost
identical results to a simple model that makes no adjustment.
We explored the theoretical reasons why rare events lead to
the models giving the same results and used constructed data
to identify situations in which the models would disagree,
and adjustments would be necessary. We also conducted a
simple simulation study to explore the impact of increasing
event rates on the bias and coverage of the simple and shared
parameter models, confirming that the latter performs better
TABLE 4 Comparison of constructed data results for apixaban vs warfarin
Scenario Outcome
Adjusted HRa
Mean (95% CrI)
Simple ORb
Mean (95% CrI) Event Ratec
Base rate Ischaemic stroke 0.901 (0.729, 1.11) 0.913 (0.734, 1.13) 0.0101
MI 0.832 (0.655, 1.06) 0.874 (0.666, 1.14) 0.00584
Death (all causes) 0.887 (0.798, 0.986) 0.883 (0.792, 0.986) 0.0366
Clinically relevant bleeding 0.811 (0.693, 0.945) 0.812 (0.696, 0.95) 0.0207
Inflate by 2 Ischaemic stroke 0.909 (0.783, 1.06) 0.913 (0.784, 1.07) 0.0202
MI 0.864 (0.711, 1.05) 0.874 (0.72, 1.06) 0.0117
Death (all causes) 0.893 (0.827, 0.963) 0.876 (0.809, 0.949) 0.0732
Clinically relevant bleeding 0.807 (0.722, 0.901) 0.807 (0.721, 0.902) 0.0415
Inflate by 5 Ischaemic stroke 0.915 (0.832, 1.01) 0.909 (0.822, 1) 0.0505
MI 0.873 (0.771, 0.99) 0.87 (0.767, 0.986) 0.0292
Death (all causes) 0.896 (0.853, 0.941) 0.847 (0.798, 0.9) 0.183
Clinically relevant bleeding 0.804 (0.751, 0.862) 0.785 (0.728, 0.844) 0.104
Inflate by 10 Ischaemic stroke 0.915 (0.855, 0.979) 0.899 (0.834, 0.968) 0.101
MI 0.876 (0.802, 0.958) 0.864 (0.788, 0.946) 0.0584
Death (all causes) 0.897 (0.866, 0.928) 0.697 (0.654, 0.743) 0.366
Clinically relevant bleeding 0.801 (0.762, 0.842) 0.734 (0.692, 0.78) 0.207
Inflate by 20 Ischaemic stroke 0.917 (0.874, 0.961) 0.871 (0.821, 0.925) 0.202
MI 0.877 (0.823, 0.934) 0.848 (0.791, 0.91) 0.117
Death (all causes) 0.999 (0.97, 1.03) 0.0429 (4.33e-06, 106)d 0.581
Clinically relevant bleeding 0.801 (0.773, 0.83) 0.499 (0.469, 0.532) 0.415
Notes. Results are shaded if the 95% credible intervals do not overlap.
aAdjusted HR is the hazard ratio estimated by the model accounting for competing risks and differently reported data.
bSimple OR is the odds ratio estimated by the model that disregards competing risks and differently reported data.
cAveraged over all arms and all trials.
dAnomalous results due to high event rate.
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when events are more common and that the crossover point
for rates is between 0.1 and 0.3. Although our example
was in NMA, the conclusion is general to meta-analysis of
multiple outcomes or where different data summaries are
used.
Shared parameter and competing risk NMAs have been
previously published but not specifically for the data formats
used in our example.23,38,39 Woods et al presents a shared
parameter model but analyses only a single outcome and
combines studies that report mean or median survival with
studies that report total numbers of events.23 We instead ana-
lyze multiple outcomes accounting for competing risks and
combine studies that summarize the numbers of events dif-
ferently. Shared parameter models (such as ours) are specific
examples of a more general multiparameter evidence synthe-
sis (MPES) framework.38,39 Competing risk NMA has been
studied in the literature,1 but this earlier work assumes that
all studies report data in the same way. Our work can be con-
sidered an extension of previous developments in shared
parameter models and competing risks within the more gen-
eral MPES framework. However, there are several issues to
consider when drawing conclusions from our study.
Meta-analysis and NMA are the recommended approach
for treatment effect estimation and indirect comparison by
health care authorities and international medical decision-
making societies.7,8 It is therefore important to ensure that
unbiased methods are used. Meta-analysis and NMA results
may also be used as inputs to cost-effectiveness models.13
As treatment effects on multiple outcomes must be simulta-
neously estimated, it is important to account for competing
risks; this is relevant to our atrial fibrillation example as the
estimates were used in a cost-effectiveness model.26,27 Also,
although clinical conclusions may not be sensitive to adjust-
ment for competing risks or different data summaries, the
cost-effectiveness results may be impacted. This has been
the finding in work considering different synthesis models in
type 1 diabetes where clinical conclusions were unaffected
but cost-effectiveness conclusions changed.14 The
TABLE 5 Comparison of constructed data results for dabigatran vs warfarin
Scenario Outcome
Adjusted HRa
Mean (95% CrI)
Simple ORb
Mean (95% CrI) Event Ratec
Base rate Ischaemic stroke 0.751 (0.583, 0.969) 0.757 (0.583, 0.978) 0.00845
MI 1.25 (0.932, 1.68) 1.29 (0.949, 1.75) 0.00796
Death (all causes) 0.886 (0.78, 1.01) 0.882 (0.772, 1.01) 0.0359
Clinically relevant bleeding 1.07 (0.916, 1.24) 1.08 (0.925, 1.26) 0.0299
Inflate by 2 Ischaemic stroke 0.752 (0.627, 0.904) 0.754 (0.628, 0.907) 0.0169
MI 1.27 (1.03, 1.57) 1.29 (1.04, 1.61) 0.0159
Death (all causes) 0.882 (0.807, 0.968) 0.873 (0.79, 0.964) 0.0719
Clinically relevant bleeding 1.07 (0.966, 1.19) 1.09 (0.973, 1.22) 0.0597
Inflate by 5 Ischaemic stroke 0.753 (0.67, 0.846) 0.74 (0.655, 0.835) 0.0423
MI 1.29 (1.12, 1.48) 1.31 (1.14, 1.51) 0.0398
Death (all causes) 0.863 (0.814, 0.915) 0.831 (0.772, 0.893) 0.18
Clinically relevant bleeding 1.08 (1.01, 1.15) 1.11 (1.03, 1.2) 0.149
Inflate by 10 Ischaemic stroke 0.739 (0.68, 0.803) 0.713 (0.652, 0.78) 0.0845
MI 1.31 (1.19, 1.43) 1.34 (1.21, 1.48) 0.0796
Death (all causes) 0.771 (0.737, 0.806) 0.611 (0.561, 0.665) 0.359
Clinically relevant bleeding 1.08 (1.03, 1.13) 1.2 (1.11, 1.29) 0.299
Inflate by 20 Ischaemic stroke 0.703 (0.662, 0.745) 0.639 (0.594, 0.688) 0.169
MI 1.34 (1.26, 1.44) 1.41 (1.31, 1.53) 0.159
Death (all causes) 1.89 (0.285, 19.2) 86.1 (0.0001, 1.49e+09)d 0.499
Clinically relevant bleeding 1 (0.966, 1.04) 8.5 (0.00728, 8334)d 0.5
Notes. Results are shaded if the 95% credible intervals do not overlap.
aAdjusted HR is the hazard ratio estimated by the model accounting for competing risks and differently reported data.
bSimple OR is the odds ratio estimated by the model that disregards competing risks and differently reported data.
cAveraged over all arms and all trials.
dAnomalous results due to high event rate.
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FIGURE 1 Comparison of estimated
adjusted HR (dotted) and simple OR
(solid) for apixaban under constructed data
scenarios. Thin lines represent upper and
lower 95% credible interval limits
FIGURE 2 Comparison of estimated
adjusted HR (dotted) and simple OR
(solid) for dabigatran under constructed
data scenarios. Thin lines represent upper
and lower 95% credible interval limits
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correlation matrix between apixaban hazard ratios of events
is presented in Table 11, with other matrices in the
Supporting Information. This demonstrates that the hazard
ratio estimates were correlated. The simple model assumes
these correlations to be zero, and an economic model based
could be biased by omission of this correlation.
TABLE 6 Simulation study bias results on outcome 1
Average Event Rate Outcome 1 Average Event Rate Outcome 2 0.05 0.1 0.2 0.3 0.4
0.05 Simple 0.0058 0.0057 0.0061 0.0060 0.0062
Complex 0.0073 0.0067 0.0066 0.0064 0.0064
0.1 Simple 0.0040 0.0042 0.0043 0.0046 0.0047
Complex 0.0045 0.0045 0.0043 0.0045 0.0043
0.2 Simple 0.0031 0.0032 0.0036 0.0038 0.0039
Complex 0.0031 0.0031 0.0030 0.0030 0.0030
0.3 Simple 0.0031 0.0033 0.0037 0.0041 0.0043
Complex 0.0026 0.0026 0.0025 0.0025 0.0025
0.4 Simple 0.0037 0.0041 0.0046 0.0051 0.0056
Complex 0.0022 0.0023 0.0022 0.0022 0.0022
Notes. Greater values indicate worse performance. Simple is simple odds ratio NMAwhile complex is shared parameter NMA.
TABLE 7 Simulation study bias results on outcome 2
Average Event Rate Outcome 1 Average Event Rate Outcome 2 0.05 0.1 0.2 0.3 0.4
0.05 Simple 0.0061 0.0042 0.0031 0.0029 0.0029
Complex 0.0079 0.0047 0.0030 0.0025 0.0021
0.1 Simple 0.0061 0.0044 0.0033 0.0030 0.0034
Complex 0.0076 0.0046 0.0031 0.0024 0.0022
0.2 Simple 0.0063 0.0045 0.0036 0.0035 0.0038
Complex 0.0076 0.0047 0.0031 0.0025 0.0021
0.3 Simple 0.0064 0.0047 0.0038 0.0039 0.0042
Complex 0.0074 0.0047 0.0031 0.0025 0.0021
0.4 Simple 0.0065 0.0048 0.0039 0.0040 0.0045
Complex 0.0074 0.0047 0.0032 0.0025 0.0021
Notes. Greater values indicate worse performance. Simple is simple odds ratio NMAwhile complex is shared parameter NMA.
TABLE 8 Simulation study mean coverage probability results on outcome 1
Average Event Rate Outcome 1 Average Event Rate Outcome 2 0.05 0.1 0.2 0.3 0.4
0.05 Simple 0.952 0.958 0.940 0.945 0.932
Complex 0.851 0.874 0.870 0.868 0.856
0.1 Simple 0.956 0.948 0.947 0.928 0.925
Complex 0.924 0.924 0.927 0.913 0.924
0.2 Simple 0.958 0.947 0.919 0.907 0.888
Complex 0.945 0.950 0.948 0.948 0.947
0.3 Simple 0.924 0.900 0.853 0.826 0.790
Complex 0.948 0.942 0.951 0.955 0.952
0.4 Simple 0.844 0.796 0.724 0.663 0.589
Complex 0.944 0.951 0.952 0.952 0.957
Notes. Greater values indicate better performance. Simple is simple odds ratio NMAwhile complex is shared parameter NMA.
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Our finding from both the constructed data and simula-
tion study was that event rates above 0.2 might warrant con-
sideration of different data summaries and competing risks.
Below this level, however, our simulation study suggests that
the simple odds ratio model may be preferred. A possible
explanation for the superior performance on rare event data
of the simple model is influence of the prior distributions,
which have greater impact due to the larger number of
parameters in the shared parameter model. However, our
simulation study for vague priors in the shared parameter
model indicates that bias and coverage are not improved
when vaguer priors are used. In addition, convergence can
become an issue when vague priors are assumed for the
shared parameter model.
The sensitivity to competing risks has been identified in
NMA examples,4 and our approximate threshold 0.2 is in
line with a previous informal assessment to the sensitivity of
using odds and hazard ratios.32 Although event rates in our
atrial fibrillation example were below the 0.2 threshold, rates
above this level are common in other fields, including
response and remission in depression,9 annualized relapse
TABLE 10 Vague priors for complex model simulation study results
Outcome 1 Results Outcome 2 Results
Model
Outcome 2 Average Rate 0.05 0.1 0.05 0.1
Outcome 1 Average Rate
Bias Simple 0.05 0.0060 0.0062 0.0056 0.0040
Complex 0.0078 0.0077 0.0071 0.0044
Simple 0.1 0.0042 0.0044 0.0060 0.0043
Complex 0.0047 0.0047 0.0070 0.0046
Coverage Simple 0.05 0.959 0.946 0.957 0.958
Complex 0.860 0.862 0.863 0.932
Simple 0.1 0.961 0.946 0.947 0.948
Complex 0.930 0.930 0.863 0.913
Notes. Mean bias and mean coverage for both outcome 1 and outcome 2. Greater coverage and lower bias indicate better performance. Results can be compared with
upper left corners of Tables 7 to 10.
TABLE 9 Simulation study mean coverage probability results on outcome 2
Average Event Rate Outcome 1 Average Event Rate Outcome 2 0.05 0.1 0.2 0.3 0.4
0.05 Simple 0.945 0.954 0.962 0.949 0.926
Complex 0.851 0.926 0.961 0.964 0.967
0.1 Simple 0.954 0.951 0.950 0.930 0.888
Complex 0.867 0.938 0.953 0.959 0.957
0.2 Simple 0.944 0.939 0.925 0.896 0.831
Complex 0.854 0.928 0.950 0.961 0.970
0.3 Simple 0.932 0.933 0.901 0.852 0.786
Complex 0.862 0.919 0.953 0.956 0.970
0.4 Simple 0.937 0.927 0.892 0.846 0.744
Complex 0.847 0.912 0.942 0.952 0.964
Notes. Greater values indicate better performance. Simple is simple odds ratio NMAwhile complex is shared parameter NMA.
TABLE 11 Correlation matrix for hazard ratios of events of
interest for apixaban
MI
Ischaemic
Stroke
Death
(All
Causes)
Clinically
Relevant
Bleeding
MI 1.000 0.028 −0.007 0.017
Ischaemic
stroke
0.028 1.000 0.012 −0.027
Death (all
causes)
−0.007 0.012 1.000 −0.022
Clinically
relevant
bleeding
0.017 −0.027 −0.022 1.000
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rates in relapsing remitting multiple sclerosis,11 and 5-year
survival and mortality rates in a range of cancers.12 Despite
this sensitivity, high profile NMAs continue not to adjust for
competing risks or consider different data summaries when
analyzing multiple outcomes.10
There are important limitations to our analysis. We did
not use theoretical analysis to estimate the event rate thresh-
old below which competing risks and different data summa-
ries can be ignored; our informal threshold came only from
constructed data analyses and a simple simulation study.
Estimating this threshold, or identifying conditions under
which competing risks and data summaries cannot be
ignored, by asymptotic arguments may be worthwhile future
research. Although our simulation study, unlike the con-
structed data example, explored differential event rates, we
did not formally assess correlation.
6 | CONCLUSIONS
In this paper, we have considered a NMA where the RCTs
report results on competing risks in different formats. We
developed a novel shared parameter model accounting for all
these complications. Applying this model to a synthesis of
interventions for atrial fibrillation however, results were
almost identical to a model without the necessary adjust-
ments. We used theoretical arguments to demonstrate that
this is due to the rareness of events. We further used con-
structed data examples and a simulation study to find situa-
tions in which the adjustments may become necessary. We
recommend analysts to consider the absolute event rates and
only use a simple model ignoring data types and competing
risks, if all of these underlying events are rare (below our
threshold of approximately 0.2). If one or more of the abso-
lute event rates approaches or exceeds our informal thresh-
old, it is necessary to account for data types and competing
risks through a shared parameter model in order to avoid
biased estimates. A more complete simulation study could
simulate different numbers of treatments or outcomes, multi-
armed trials, sample sizes, and more varied event rates. This
was outside the scope of the present study but could be a
useful piece of future research.
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